FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Estradiol Valerate Injection, USP
Status: Currently in Shortage
»Date first posted: 08/10/2016
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Par Pharmaceutical (Revised 04/21/2017)

Company Contact Information:
201-802-4000

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Delestrogen® (estradiol valerate injection, USP) 10 mg/mL, 5 mL vial: (NDC 42023-110-01) All presentations are available. Par is the sole source for the 10mg strength. Other
Delestrogen® (estradiol valerate injection, USP) 20 mg/mL, 5 mL vial: (NDC 42023-111-01) All presentations are available. Par is the sole source for the 10mg strength. Other
Delestrogen® (estradiol valerate injection, USP) 40 mg/mL, 5 mL vial: (NDC 42023-112-01) All presentations are available. Par is the sole source for the 10mg strength. Other

Perrigo Pharmaceuticals (Revised 04/18/2017)

Company Contact Information:
866-634-9120

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Estradiol Valerate Injection, USP 20 mg/mL, 5 mL vial, (NDC 0574-0870-05) Available Currently releasing product. Shortage of an inactive ingredient component
Estradiol Valerate Injection, USP 40 mg/mL, 5 mL vial, (NDC 0574-0872-05) Available Currently releasing product. Shortage of an inactive ingredient component

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English